Bachelor's in Biological Sciences at Universidade Estadual de Campinas (2004) and PhD in Clinical Medicine at Universidade Estadual de Campinas (2010). (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Acute myeloid leukemia (AML) is a severe hematologic malignancy characterized by the presence of immature hematopoietic cells in the bone marrow that impairs normal formation of blood cells. Mutations in the TP53 tumor suppressor gene (coding for p53 protein) are found in approximately 8% of AML patients and are associated with decreased therapeutic response and survival. Even though the …
Acute myeloid leukemia (AML) is a blood cell cancer that can start from the progression of myelodysplastic syndromes (MDS). Bone marrow cells from MDS and AML patients present genomic alterations that result in gene expression changes, leading to increased proliferation and decreased differentiation and apoptosis. To understand how MDS and AML progress, it is therefore important to identi…
Acute Myeloid Leukemia (AML) is a cancer originated from the accumulation of immature hematopoietic cells (blasts) in the bone marrow, characterized by low rates of patient survival. Mutations in the tumor suppressing gene TP53 are present in around 5-10% of AML cases and are associated with a worse prognosis. It is believed that the additional patients present inactivation of the TP53 pa…
Acute Myeloid Leukemia (AML) is a severe hematologic malignancy characterized by blockage in myeloid differentiation and uncontrolled proliferation of leukemic cells that accumulate in the bone marrow and blood. The TP53 gene, known as "guardian of the genome" is an important tumor suppressor encoding the p53 protein, whose inactivation is related to increased proliferation, survival and …
ARHGAP21 is a RhoGAP protein with important functions in neoplastic cells, such as migration proliferation and in the epithelial-mesenchymal transition process. ARHGAP21 expression is altered in patients with acute myeloid leukemia (AML) and in patients with head and neck cancer. Moreover, ARHGAP21 silencing in prostate cancer cells induced changes in the expression of genes involved in t…
| 1 / 1 | Ongoing research grants |
| 1 / 1 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 4 / 1 | Completed scholarships in Brazil |
| 8 / 5 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID